Investigative Ophthalmology & Visual Science Cover Image for Volume 64, Issue 8
June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Infectious keratitis treatment failure – a study of patient and microbial characteristics in Rochester, NY
Author Affiliations & Notes
  • Caroline Maretz
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Jason Atlas
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Shalini Shah
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Rachel Wozniak
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Footnotes
    Commercial Relationships   Caroline Maretz None; Jason Atlas None; Shalini Shah None; Rachel Wozniak AbbVie, Arcum Therapeutics, Code C (Consultant/Contractor), Arcum Vision, Code E (Employment)
  • Footnotes
    Support  K08 EYE29012, Research to Prevent Blindness Departmental Unrestricted Grant, Research to Prevent Blindness Career Development Award 2020
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 5164. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Caroline Maretz, Jason Atlas, Shalini Shah, Rachel Wozniak; Infectious keratitis treatment failure – a study of patient and microbial characteristics in Rochester, NY. Invest. Ophthalmol. Vis. Sci. 2023;64(8):5164.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Infectious keratitis (IK) is a devastating disease that, in some patients, can lead to blindness or even loss of the eye despite immediate and intensive topical antimicrobial therapy. To inform clinical prognosis, this retrospective, clinical study examined patient demographics, systemic and ocular comorbidities, as well as microbial data to determine those factors associated with treatment failure.

Methods : A retrospective study was conducted of 407 patients with IK at the University of Rochester, between July 2018 and December 2021 who had documented clinical follow up for at least 2 weeks. Treatment failure was defined as no clinical improvement within 2 weeks of initial presentation and/or need for surgical intervention, including corneal gluing, patch graft, transplant or evisceration. Tests of two proportions were used for statistical analysis to compare patients with treatment failure vs success with regards to a wide range of patient characteristics and microbiologic data.

Results : Of 407 patients, 62 (15.2%) experienced treatment failure, of which 37 (58.1%) required surgical intervention. The treatment failure group had significantly higher rates of Pseudomonas aeruginosa (p=0.037), fungi (p=0.008), and polymicrobial (p=0.034) cultures. Additionally, age 65+ (p=1.79e-5), systemic immunosuppression (p=0.011) and smoking history (p=0.018) were significantly associated with treatment failure. Ocular history associated with treatment failure included prior corneal transplant (p=8.33e-6), prior transplant rejection (p=1.67e-5), use of topical steroids (p=1.38e-6), history of intraocular surgery (p=2.4e-10) and visual acuity of 20/250 or worse (p=1.94e-6). Patients with treatment failure had significantly higher rates of prescribed fortified antibiotics (p=7.21e-7) and bandage contact lenses (p= 7.51e-10) during their treatment course.

Conclusions : These results highlight significant factors associated with IK treatment failure including age >65, immunosuppression, smoking history, and ocular comorbidities (including prior intraocular surgery and poor visual acuity). Patients with treatment failure were also more likely to have polymicrobial, P. aeruginosa or fungal infections. This study improves our understanding of IK by identifying key prognostic indicators of treatment failure for this blinding disease.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×